MCID: HPT021
MIFTS: 68

Hepatitis

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Mental diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 12 73 29 54 6 42 15 37 70
Chronic Persistent Hepatitis 12 54 70
Chronic Hepatitis 12 15 17
Hepatitis, Chronic 44 70
Acute Hepatitis 12 70
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Hepatitis Chronic 54
Hepatitis, Animal 70
Animal Hepatitis 12
Hepatitis a 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2237
ICD9CM 34 570 571.4 571.41
MeSH 44 D006521
NCIt 50 C82978
ICD10 32 K73 K73.0 K73.9
UMLS 70 C0001308 C0019158 C0019159 more

Summaries for Hepatitis

MedlinePlus : 42 What is hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What causes hepatitis? There are different types of hepatitis, with different causes: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A, B, C, D, and E. In the United States, A, B, and C are the most common. Alcoholic hepatitis is caused by heavy alcohol use Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements Autoimmune hepatitis is a chronic type in which your body's immune system attacks your liver. The cause is not known, but genetics and your environment may play a role. How is viral hepatitis spread? Hepatitis A and hepatitis E usually spread through contact with food or water that was contaminated with an infected person's stool. You can also get hepatitis E by eating undercooked pork, deer, or shellfish. Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and D may also spread through contact with other body fluids. This can happen in many ways, such as sharing drug needles or having unprotected sex. Who is at risk for hepatitis? The risks are different for the different types of hepatitis. For example, with most of the viral types, your risk is higher if you have unprotected sex. People who drink a lot over long periods of time are at risk for alcoholic hepatitis. What are the symptoms of hepatitis? Some people with hepatitis do not have symptoms and do not know they are infected. If you do have symptoms, they may include Fever Fatigue Loss of appetite Nausea and/or vomiting Abdominal pain Dark urine Clay-colored bowel movements Joint pain Jaundice, yellowing of your skin and eyes If you have an acute infection, your symptoms can start anywhere between 2 weeks to 6 months after you got infected. If you have a chronic infection, you may not have symptoms until many years later. What other problems can hepatitis cause? Chronic hepatitis can lead to complications such as cirrhosis (scarring of the liver), liver failure, and liver cancer. Early diagnosis and treatment of chronic hepatitis may prevent these complications. How is hepatitis diagnosed? To diagnose hepatitis, your health care provider Will ask about your symptoms and medical history Will do a physical exam Will likely do blood tests, including tests for viral hepatitis Might do imaging tests, such as an ultrasound, CT scan, or MRI May need to do a liver biopsy to get a clear diagnosis and check for liver damage What are the treatments for hepatitis? Treatment for hepatitis depends on which type you have and whether it is acute or chronic. Acute viral hepatitis often goes away on its own. To feel better, you may just need to rest and get enough fluids. But in some cases, it may be more serious. You might even need treatment in a hospital. There are different medicines to treat the different chronic types of hepatitis. Possible other treatments may include surgery and other medical procedures. People who have alcoholic hepatitis need to stop drinking. If your chronic hepatitis leads to liver failure or liver cancer, you may need a liver transplant. Can hepatitis be prevented? There are different ways to prevent or lower your risk for hepatitis, depending on the type of hepatitis. For example, not drinking too much alcohol can prevent alcoholic hepatitis. There are vaccines to prevent hepatitis A and B. Autoimmune hepatitis cannot be prevented. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis a and hepatitis b, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Measles and Toll-like Receptor Signaling Pathway. The drugs Sargramostim and glycyrrhizin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms,... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2224)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 33.5 SEPSECS IFNA1 HAVCR2 HAVCR1 GPT
2 hepatitis b 33.4 SLC10A1 RSF1 NR5A2 LAMTOR5 IFNAR2 IFNA2
3 viral hepatitis 33.4 SEPSECS KRT8 IFNA2 IFNA1 GPT
4 hepatitis c 33.4 SCARB1 KRT8 IFNAR2 IFNA2 IFNA1 GPT
5 hepatitis c virus 33.3 SCARB1 KRT8 HAVCR2 GPT EIF2AK2 DDX3X
6 hepatitis d 33.3 SLC10A1 IFNA2 IFNA1 GPT EIF2AK2
7 autoimmune hepatitis 33.3 SEPSECS KRT8 IFNA1 GPT ASGR2
8 liver cirrhosis 32.7 KRT8 IFNA2 IFNA1 GPT ASGR2
9 liver disease 32.7 SLC10A1 SEPSECS KRT8 IFNA2 IFNA1 GPT
10 cryoglobulinemia, familial mixed 32.4 IFNA2 IFNA1
11 cryoglobulinemia 32.2 IFNA2 IFNA1 GPT
12 autoimmune cholangitis 31.7 SEPSECS IFNA2
13 viral infectious disease 31.6 IFNAR2 IFNA2 IFNA1 GPT EIF2AK2 CLEC4M
14 cholangitis, primary sclerosing 31.4 SLC10A1 SEPSECS GPT
15 stomatitis 31.3 IFNA2 IFNA1 EIF2AK2
16 mumps 31.2 IFNAR2 IFNA1 EIF2AK2
17 discoid lupus erythematosus 30.2 IFNA2 IFNA1
18 suppurative cholangitis 30.2 SEPSECS GPT
19 west nile fever 30.0 IFNA1 CLEC4M
20 pyuria 29.8 HAVCR1 GPT
21 hepatitis e 11.8
22 alcoholic hepatitis 11.6
23 non-a-e hepatitis 11.5
24 hepatocellular carcinoma 11.4
25 hepatitis, fulminant viral 11.4
26 hemochromatosis, neonatal 11.4
27 drug-induced hepatitis 11.4
28 acute liver failure 11.3
29 epstein-barr virus hepatitis 11.3
30 fatty liver disease 11.3
31 granulomatous hepatitis 11.3
32 halothane hepatitis 11.2
33 gianotti crosti syndrome 11.2
34 australia antigen 11.2
35 hepatitis b vaccine, response to 11.1
36 polyarteritis nodosa 11.1
37 non-alcoholic fatty liver disease 11.1
38 immune deficiency disease 11.1
39 seronegative autoimmune hepatitis 11.1
40 lichen planus 11.1
41 membranous nephropathy 11.0
42 aplastic anemia 11.0
43 fibrosis of extraocular muscles, congenital, 1 11.0
44 porphyria cutanea tarda 11.0
45 autoimmune hepatitis type 1 11.0
46 wilson disease 11.0
47 autoimmune hepatitis type 2 11.0
48 hepatoblastoma 11.0
49 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.0
50 glomerulonephritis 10.9

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hepatic Encephalopathy
Hypothyroidism Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; hepatosplenomegaly; dyspepsia; lameness, animal; icterus; heartburn; gastrointestinal gas; hepatocellular jaundice

GenomeRNAi Phenotypes related to Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.5 EIF2AK2
2 Decreased viability GR00221-A-2 9.5 EIF2AK2
3 Decreased viability GR00221-A-3 9.5 EIF2AK2
4 Decreased viability GR00221-A-4 9.5 EIF2AK2
5 Decreased viability GR00249-S 9.5 CLDN6 LMBRD1 NR5A2
6 Decreased viability GR00301-A 9.5 EIF2AK2
7 Decreased viability GR00386-A-1 9.5 ASGR2 CLEC4M NR5A2
8 Decreased viability GR00402-S-2 9.5 GPT KRT8 NR5A2 SLC10A1

MGI Mouse Phenotypes related to Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.47 ASGR2 CLDN6 CLEC4M DDX3X EIF2AK2 HAVCR2

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 943)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
2
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
3
Simvastatin Approved Phase 4 79902-63-9 54454
4
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
7
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
8
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
9
parecoxib Approved Phase 4 198470-84-7
10
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
11
Simethicone Approved Phase 4 8050-81-5
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
15
Aluminum sulfate Approved Phase 4 10043-01-3
16
Losartan Approved Phase 4 114798-26-4 3961
17
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
18
Fosamprenavir Approved Phase 4 226700-79-4 131536
19
Zidovudine Approved Phase 4 30516-87-1 35370
20
Meperidine Approved Phase 4 57-42-1 4058
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
23
Polyestradiol phosphate Approved Phase 4 28014-46-2
24
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
25
Atorvastatin Approved Phase 4 134523-00-5 60823
26
Desflurane Approved Phase 4 57041-67-5 42113
27
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
28
Insulin aspart Approved Phase 4 116094-23-6 16132418
29
Didanosine Approved Phase 4 69655-05-6 50599
30
Nelfinavir Approved Phase 4 159989-64-7 64143
31
Azathioprine Approved Phase 4 446-86-6 2265
32
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
33
Pancrelipase Approved, Investigational Phase 4 53608-75-6
34
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
35
Pentetic acid Approved Phase 4 67-43-6
36
Edetic Acid Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
37
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
38
Ziprasidone Approved Phase 4 146939-27-7 60854
39
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
40
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
41
Tigecycline Approved Phase 4 220620-09-7 5282044
42
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
43
Baclofen Approved Phase 4 1134-47-0 2284
44
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
45
Deferiprone Approved Phase 4 30652-11-0 2972
46
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
47
Remifentanil Approved Phase 4 132875-61-7 60815
48
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
49
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
50
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548

Interventional clinical trials:

(show top 50) (show all 5771)
# Name Status NCT ID Phase Drugs
1 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
2 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
3 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
4 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
5 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
6 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
7 Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
8 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
9 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
10 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
11 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
12 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
13 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
14 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
15 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
16 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
17 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
18 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X) Unknown status NCT03801538 Phase 4 Peginterferon Alfa;Nucleoside Analog (Substance)
19 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
20 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
21 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02745704 Phase 4 Peginterferon alfa
22 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
23 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
24 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
25 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02838810 Phase 4 peginterferon alfa;Nucleoside analogues
26 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
27 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
28 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
29 A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml. Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
30 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
31 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
32 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
33 The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209011 Phase 4 Peginterferon Alfa-2a
34 The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B. Unknown status NCT03208998 Phase 4 Peginterferon Alfa-2a
35 HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha Unknown status NCT02908763 Phase 4 peginterferon alfa
36 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
37 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
38 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
39 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
40 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
41 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
42 An Open-label Rollover Study in Chinese Patients After Finishing a 3-year Randomize Trial for Chronic Hepatitis B With High Serum Viral Load But Mild Elevated Aminotransferase Unknown status NCT02463019 Phase 4 Tenofovir Disoproxil Fumarate
43 The Optimizing Treatment of Peginterferon Alpha in HBeAg-negative Chronic Hepatitis B Virus Patients With Low Level HBsAg Unknown status NCT02893124 Phase 4 peginterferon alfa
44 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
45 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
46 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
47 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
48 Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients Unknown status NCT03332329 Phase 4 Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
49 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
50 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ASTRAGALUS EXTRACT PWDR
Astragalus preparation
Milk thistle extract

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera HepaStem, human adult liver progenitor cells for liver diseases
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 24142276 22900053 19091822

Cochrane evidence based reviews: hepatitis, chronic

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

40
Liver, Kidney, T Cells, Bone, Bone Marrow, Colon, Endothelial

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 31678)
# Title Authors PMID Year
1
Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study. 61 42
33170847 2020
2
Hepatic actinomycosis: a very rare form of actinomycosis. 42
33681913 2021
3
COVID-19 epidemic in the US-A gateway to screen for tuberculosis, HIV, viral hepatitides, Chagas disease, and other neglected tropical diseases among Hispanics. 42
33338043 2020
4
Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. 61 54
19788696 2010
5
Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. 61 54
18996424 2009
6
[Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation]. 61 54
19119247 2008
7
Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. 54 61
18410611 2008
8
Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. 61 54
18339114 2008
9
[An analysis of the clinical characteristics of patients with chronic hepatitis B superinfected with acute hepatitis E]. 54 61
18322591 2007
10
Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. 61 54
17389454 2007
11
Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. 61 54
17465484 2007
12
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B. 54 61
17133546 2007
13
Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. 54 61
16899594 2006
14
Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation? 61 54
16390851 2006
15
Early reduction of infected hepatocytes by activated immunity at the time of interferon withdrawal hepatitis followed by lamivudine administration resulted in higher seroconversion in hepatitis Be antigen-positive patients with chronic hepatitis B. 54 61
16568374 2006
16
Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. 61 54
16437596 2005
17
Autoimmune hepatitis triggered by acute hepatitis A. 54 61
16273628 2005
18
Influence of load of hepatitis A virus on disease severity and its relationship with clinical manifestations in patients with hepatitis A. 61 54
16048563 2005
19
Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. 54 61
15962221 2005
20
Prolonged acute hepatitis A mimicking autoimmune hepatitis. 61 54
15968741 2005
21
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. 61 54
15756144 2005
22
Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. 54 61
15926860 2005
23
Infectious source factors affecting the severity of sexually transmitted acute hepatitis due to hepatitis B virus genotype C. 54 61
15812183 2005
24
Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus. 54 61
15086601 2004
25
[Interrelation between the activity of hepatitis, liver fibrosis and immune status in children with chronic hepatitis B and C]. 54 61
15188560 2004
26
Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. 61 54
15564749 2004
27
Different hepatitis C virus dynamics of free-virions and immune-complexes after initiation of interferon-alpha in patients with chronic hepatitis C. 61 54
14642620 2003
28
[HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis]. 54 61
14972004 2003
29
Does previous hepatitis A infection affect the clinicopathological status of chronic hepatitis C? 61 54
12845983 2003
30
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha. 61 54
12594208 2003
31
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C]. 61 54
12501575 2002
32
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. 61 54
12399221 2002
33
Polyphyletic strains of hepatitis E virus are responsible for sporadic cases of acute hepatitis in Japan. 54 61
12202555 2002
34
Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C. 61 54
12010510 2002
35
Interferon therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after treatment of recurrent hepatocellular carcinoma: a successful case. 61 54
11929181 2002
36
Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. 61 54
11807019 2002
37
Development of multicentric hepatocellular carcinoma after completion of interferon therapy. 61 54
12203085 2002
38
Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. 54 61
11808938 2002
39
Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. 61 54
11523696 2001
40
Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. 54 61
11343230 2001
41
Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. 61 54
11316166 2001
42
Immunohistochemical assessment and prognostic value of hepatitis B virus X protein in chronic hepatitis and primary hepatocellular carcinomas using anti-HBxAg monoclonal antibody. 54 61
11692143 2001
43
Expression of transforming growth factor beta-1 in chronic hepatitis and hepatocellular carcinoma associated with hepatitis C virus infection. 61 54
11242803 2000
44
Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. 61 54
10761457 2000
45
Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. 61 54
10718941 2000
46
Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis. 61 54
10553026 1999
47
Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. 61 54
10363572 1999
48
Autoantibody to the liver arginase present in sera of patients with autoimmune hepatitis and chronic hepatitis. 54 61
10520898 1999
49
Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha. 61 54
9857350 1998
50
De novo hepatitis C in children after liver transplantation. 61 54
9721798 1998

Variations for Hepatitis

ClinVar genetic disease variations for Hepatitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MT-TL1 NC_012920.1:m.3275C>T SNV Uncertain significance 370045 rs1057516057 GRCh37: MT:3275-3275
GRCh38: MT:3275-3275

Copy number variations for Hepatitis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

GO Terms for Hepatitis

Cellular components related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apicolateral plasma membrane GO:0016327 8.62 KRT8 CLDN6

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.56 IFNAR2 IFNA2 IFNA1 EIF2AK2
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.54 HAVCR2 EIF2AK2 DDX3X
3 T cell activation involved in immune response GO:0002286 9.51 IFNA2 IFNA1
4 type I interferon signaling pathway GO:0060337 9.5 IFNAR2 IFNA2 IFNA1
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.49 IFNA2 IFNA1
6 natural killer cell activation involved in immune response GO:0002323 9.48 IFNA2 IFNA1
7 protein localization to lysosome GO:0061462 9.46 LMBRD1 LAMTOR5
8 response to virus GO:0009615 9.46 LAMTOR5 IFNAR2 EIF2AK2 DDX3X
9 viral genome replication GO:0019079 9.43 LAMTOR5 CLEC4M
10 response to interferon-alpha GO:0035455 9.4 IFNAR2 EIF2AK2
11 viral process GO:0016032 9.36 SLC10A1 SCARB1 LMBRD1 KRT8 HAVCR1 EIF2AK2
12 viral entry into host cell GO:0046718 9.35 SLC10A1 SCARB1 HAVCR1 CLEC4M CLDN6

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.02 SLC10A1 SCARB1 HAVCR1 CLEC4M CLDN6
2 type I interferon receptor binding GO:0005132 8.96 IFNA2 IFNA1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....